CMS Open Payments · Program Year 2024
Ferring SA de CV
Ferring SA de CV reported $18,026.97 across General Payments, Research, and Ownership to 10 physicians and teaching hospitals across 10 transactions.
- $18.0K
- All-tracks total
- 10
- Transactions
- 10
- Recipients
- #1548
- of 1,925 companies
Ferring SA de CV reported $18,026.97 across all CMS Open Payments tracks (General + Research + Ownership) to 10 physicians and teaching hospitals in Program Year 2024 - ranking #1548 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $18,026.97, averaging $1.8K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer ferring-sa-de-cv Ferring SA de CV
$18.0K · #1548/1,925 · 0.0% industry · PY2024
- TOT $18.0K
- RANK #1548
- SHARE 0.0%
- TXN 10
- RCP 10
- CAT 3
- GEN $18.0K
- TOP1 51.3%
- PY 2024
Volume peers
Nearest volume peer: Solco Biomedical Corporation ($18.0K)
Ferring SA de CV sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Ferring SA de CV
Rank #1548 of 1,925 companies in CMS Open Payments for 2024 belongs to Ferring SA de CV, which reported $18,026.97 across 10 transactions to 10 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $1.8K per transaction and $1.8K per recipient.
2 transactions worth $13.3K make "Consulting Fee" the top general-payment category in the 3-category breakdown below, 73.9% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Ferring SA de CV's 3-category general-payment breakdown at $13.3K, 73.9% of the reported total.
How Ferring SA de CV divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $13.3K | 2 | 73.9% |
| Travel and Lodging | $3.8K | 6 | 21.1% |
| Food and Beverage | $893.90 | 2 | 5.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $18,026.97 (100.0%) of $18,026.97 in this company's General Payments records across 2 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Ferring SA de CV
The five named recipients with the highest reported General Payments from this company
- 1
Richard Legro
$9,239.32 across 5 reported transactions
- 2
Julio Loret de Mola
$8,787.65 across 5 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Ferring SA de CV's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Ferring SA de CV.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Ferring SA de CV.
Showing 6 of 1,924 companies with CMS-reported payment data.
Centrix Inc
Avantec Vascular Corporation
Ostial Corporation
Bayer Puerto Rico Inc.
Jubilant DraxImage Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.